Pulmonary surfactant is a critical component of lung function in healthy individuals. It
functions in part by lowering surface tension in the alveoli, thereby allowing for breathing …

Background Acute respiratory distress syndrome (ARDS) is a life‐threatening condition
caused by direct or indirect injury to the lungs. Despite improvements in clinical …

Рекомендации Общероссийской общественной организации «Федерация
анестезиологов и реаниматологов» посвящены современному состоянию проблемы …

Purpose Multiple interventions have been tested in acute respiratory distress syndrome
(ARDS). We examined the entire agenda of published randomized controlled trials (RCTs) …

Inhaled substances, such as consumer products, chemicals at the workplace, and
nanoparticles, can affect the lung function in several ways. In this paper, we explore the …

Background: Severe pneumonia caused by coronavirus disease 2019 (COVID-19) is
characterized by inflammatory lung injury, progressive parenchymal stiffening and …

Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical
efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells …

Acute lung injury and acute respiratory distress syndrome (ARDS) are characterised by
severe hypoxemic respiratory failure and poor lung compliance. Despite advances in clinical …

Respiratory distress syndrome (RDS) in premature infants is caused by insufficient amounts
of endogenous lung surfactant and is efficiently treated with replacement therapy using …

Acute respiratory distress syndrome (ARDS) is characterized by an excessive pulmonary
inflammatory response. Removal of excess cholesterol from the plasma membrane of …